Effects of losartan on hypertension and left ventricular mass: A long-term study

Journal of Human Hypertension

Volumn 12, Issue 8, 1998, Pages 505-510

  Tedesco, M A ^a,c   Ratti, G ^a   Aquino, D ^a   Limongelli, G ^a   Di Salvo, G ^a   Mennella, S ^a   Galzerano, D ^b   Iarussi, D ^a   Iacono, A ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Hospital Nuovo Pellegrini   (Italy)

^c NONE   (Italy)

Author keywords

Angiotensin II receptor antagonist; Essential hypertension; Left ventricular mass

Indexed keywords

ANGIOTENSIN II ANTAGONIST; HYDROCHLOROTHIAZIDE; LOSARTAN;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; ASTHENIA; BLOOD CHEMISTRY; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HEMATOLOGY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; THROAT DISEASE; VERTIGO;

EID: 0031679918     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000685     Document Type: Article

References (39)

1. Borhani NO. Prevalence and natural history of left ventricular hypertrophy in hypertension. J Clin Hypertens 1987; 3: 104-111.
2. Dal Palù C et al. Epidemiology of left ventricular hypertrophy in hypertension. J Clin Hypertens 1987; 3: 211-215.
3. Devereux RB et al. Echocardiographic detection of pressure-overload left ventricular hypertrophy: effect of criteria and patient population. J Clin Hypertens 1987; 3: 66-78.
4. Levy D et al. Prognostic implication of echocardiographically determined left ventricular mass in Framingham Heart study. N Engl J Med 1990; 332: 1561-1566.
5. Koren MJ et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 144: 345-352.
6. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
7. Hansson L, Dahlöf B, Himmelmann A, Svensson A. Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension. In: Robertson JIS, Nicholls MG (eds). The renin-angiotensin system. Gower Medical Publishing: London, 1993, pp 1-24.
8. Laragh JH, Sealey JE. The renin-angiotensin-aldosterone system in hypertensive disorders: two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis: In: Laragh JH, Brenner MB (eds): Hypertension: pathophysiology, diagnosis and management. Raven Press: New York, 1990, pp 1392-1398.
9. Husain A. The chimase-angiotensin system in humans. J Hypertens 1993; 11: 1155-1159.
10. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens 1993 11 (Suppl 3): S49-S52.
11. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
12. Siegl PKS. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens 1993; 11 (Suppl 3): S19-S22.
13. Weber MA. Clinical experience with the angiotensin II receptors antagonist losartan: a preliminary report. Am J Hypertens 1992; 5: S247-S251.
14. Brunner HR, Nussberger J, Waeber B. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens 1993; 11 (Suppl 3): S53-S58.
15. Tedesco MA et al. Antihypertensive efficacy and tolerability of losartan in hypertensive patients. In: Abstracts of 16th Scientific Meeting of the International Society of Hypertension. Glasgow, UK, 1996, S384.
16. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of method. Circulation 1977; 55: 613-618.
17. Beltman FW et al. Acceptance and side effects of ambulatory blood pressure monitoring: evaluation of new technology. J Hum Hypertens 1996; 10 (Suppl 3): S39-S42.
18. Ehlers MRW, Riordan JF. Angiotensin-converting enzyme: biochemistry and molecular biology. In: Laragh JH, Brenner BM (eds). Hypertension: pathophysiology, diagnosis and management. Raven Press: New York, 1990, pp 1217-1231.
19. Eberahardt RT, Kevak RM, Kang PM, Frishman WH. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharm 1993; 33: 1023-1028.
20. Goldberg AI, Dunlay MC, Sweet CS. The safety and tolerability of losartan potassium, an angiotensin II receptors antagonist in comparison with other antihypertensive drugs for the treatment of hypertension. Am J Cardiol 1995; 10: 793-795.
21. McIntyre M, Gaffe SE, Michalak RA, Reid L. Losartan, an orally active angiotensin (AT-1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181-194.
22. Goa KL, Wagstaff AJ. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 821-845.
23. Byyny R. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995; 15 (Suppl 1): S29-S34.
24. Weber MA et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995; 155: 405-411.
25. Wong PC et al. Non-peptide angiotensin II receptor antagonists. XI Pharmacology of EXP 3174, an active metabolite of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 255: 211-217.
26. Sweet CS et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-1040.
27. Sweet CS, Nelson EB. How well have animal studies with losartan predicted responses in humans? J Hypertens 1993; 11 (Suppl 3): S63-S67.
28. Himmelmann A et al. Losartan in essential hypertension: effects on blood pressure and left ventricular mass. High Blood Press 1995; 4: 242-248.
29. Dahlöf B, Herlitz H, Aurell M, Hansson L. Reversal of cardiovascular changes when treating essential hypertension. The renin-angiotensin-aldosterone system. Am J Hypertens 1992; 5: 900-911.
30. Dahlöf B. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. J Hypertens 1993; 11 (Suppl 3): S29-S35.
31. Tedesco MA et al. Efficacia e tollerabilità del losartan ed effetto sulla massa ventricolare sinistra in pazienti con ipertensione essenziale. Cardiologia 1998; 43: 53-59.
32. Stoll M et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657.
33. Annsov T et al. The effects of Angiotensin II receptor antagonist (AT II A) on urinary albumin excretion (UAE), left venticular mass (LVM), diastolic and systolic function and lipidic profile in essential hypertension. Nephrology 1997; 3 (Suppl 1): S520.
34. Cheung B. Increased left-ventricular mass after losartan treatment. Lancet 1997; 349: 1743-1744.
35. Kilavuz A et al. A new therapeutic approach to left ventricular hypertrophy. The 1st International Symposium on Angiotensin II antagonism, London, 28th September to 1st October, 1997, p 71.
36. Tedesco MA et al. Antihypertensive efficacy of Losartan and regression of left ventricular hypertrophy in essential hypertensives. The 1st International Symposium on Angiotensin II antagonism, London, 28th September to 1st October, 1997, p 27.
37. Bignotti M et al. Effects of chronic treatment with the Angiotensin II antagonist losartan on left ventricular anatomy and function and microalbuminuria in hypertensives. J Hypertens 1997; 15 (Suppl 4): S128.
38. De Rosa ML et al. Regression of left ventricular hypertrophy and effects on renal function during antihypertensive treatment with losartan in a two-year follow up. The 1st International Symposium on Angiotensin II antagonism, London, 28th September to 1st October, 1997, p 64.
39. Himmelmann A, Svensson A, Bergbrant A, Hansson L. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens 1996; 10: 729-734.